|
|
 Previous Article | Table of Contents | Next Article 
Administration of an anti-interleukin-6 monoclonal antibody to patients
with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma
growth and on B clinical symptoms
D Emilie, J Wijdenes, C Gisselbrecht, B Jarrousse, E Billaud, JY Blay, J Gabarre, JP Gaillard, J Brochier and M Raphael
INSERM U131, Hopital Antoine Beclere, Clamart, France.
Increased interleukin-6 (IL-6) production and expression by malignant cells
of the IL-6 receptor has been evidenced in a subgroup of non- Hodgkin's
lymphomas, suggesting that this cytokine plays a role in lymphoma growth
and in B clinical symptoms. In this study, the effect of the administration
of an anti-IL-6 monoclonal antibody (MoAb) was analyzed in 11 patients
seropositive for human immunodeficiency virus-1 and suffering from an
immunoblastic or a polymorphic large-cell lymphoma. The antibody (BE-8, 10
to 40 mg/day) was administered for 21 days. Neutralization of in vivo IL-6
effect was assessed by monitoring C-reactive protein levels in the serum.
In 5 patients, the lymphoma progressed during treatment. Among them were
the 2 patients in whom endogenous IL-6 effect was not neutralized. Five
patients experienced a stabilization, and 1 a partial remission. This
effect on lymphoma growth lasted for 8 to 28 weeks. The anti-IL-6 MoAb had
a clear effect on lymphoma-associated fever and cachexia. The mean body
weight increase was 1.4 +/- 0.5 kg between day 1 and day 21, and reached 12
kg in 120 days in 1 patient who received three courses of treatment. Side
effects were a consistent but moderate thrombocytopenia, and an occasional
and moderate decrease of neutrophil counts. Immunization against the MoAb
was observed in only 2 patients. These results indicate that in some cases
of lymphomas growth of malignant cells may be partially IL-6-dependent and
that neutralizing endogenous effect of IL-6 completely abrogates B clinical
symptoms.
Volume 84,
Issue 8,
pp. 2472-2479,
10/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Alberti, T. Bachelot, A. Duc, C. Biota, and J. Y. Blay
A Spliced Isoform of Interleukin 6 mRNA Produced by Renal Cell Carcinoma Encodes for an Interleukin 6 Inhibitor
Cancer Res.,
January 1, 2005;
65(1):
2 - 5.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi
Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence
Clin. Cancer Res.,
October 15, 2003;
9(13):
4653 - 4665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Haddad, S. Paczesny, V. Leblond, J.-M. Seigneurin, M. Stern, A. Achkar, M. Bauwens, V. Delwail, D. Debray, C. Duvoux, et al.
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
Blood,
March 15, 2001;
97(6):
1590 - 1597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cahlin, A. Körner, H. Axelsson, W. Wang, K. Lundholm, and E. Svanberg
Experimental Cancer Cachexia: The Role of Host-derived Cytokines Interleukin (IL)-6, IL-12, Interferon-{{gamma}}, and Tumor Necrosis Factor {{alpha}} Evaluated in Gene Knockout, Tumor-bearing Mice on C57 Bl Background and Eicosanoid-dependent Cachexia
Cancer Res.,
October 1, 2000;
60(19):
5488 - 5493.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Menetrier-Caux, G. Montmain, M.C. Dieu, C. Bain, M.C. Favrot, C. Caux, and J.Y. Blay
Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor
Blood,
December 15, 1998;
92(12):
4778 - 4791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J.-F. Rossi, J. Brochier, and B. Klein
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4727 - 4737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kalai, F. A. Montero-Julian, J. Grotzinger, V. Fontaine, P. Vandenbussche, R. Deschuyteneer, A. Wollmer, H. Brailly, and J. Content
Analysis of the Human Interleukin-6/Human Interleukin-6 Receptor Binding Interface at the Amino Acid Level: Proposed Mechanism of Interaction
Blood,
February 15, 1997;
89(4):
1319 - 1333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sarraf, R. C. Frederich, E. M. Turner, G. Ma, N. T. Jaskowiak, D. J. Rivet III, J. S. Flier, B. B. Lowell, D. L. Fraker, and H. R. Alexander
Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia
J. Exp. Med.,
January 1, 1997;
185(1):
171 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
